137 related articles for article (PubMed ID: 12457876)
1. The adenylate cyclase of Bordetella pertussis: a vector to target antigen presenting cells.
El Azami El Idrissi M; Ladant D; Leclerc C
Toxicon; 2002 Dec; 40(12):1661-5. PubMed ID: 12457876
[No Abstract] [Full Text] [Related]
2. The adenylate cyclase toxin from Bordetella pertussis--a novel promising vehicle for antigen delivery to dendritic cells.
Simsova M; Sebo P; Leclerc C
Int J Med Microbiol; 2004 Apr; 293(7-8):571-6. PubMed ID: 15149033
[TBL] [Abstract][Full Text] [Related]
3. Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria.
Tartz S; Kamanova J; Simsova M; Sebo P; Bolte S; Heussler V; Fleischer B; Jacobs T
Infect Immun; 2006 Apr; 74(4):2277-85. PubMed ID: 16552058
[TBL] [Abstract][Full Text] [Related]
4. Delivery of CD8(+) T-cell epitopes into major histocompatibility complex class I antigen presentation pathway by Bordetella pertussis adenylate cyclase: delineation of cell invasive structures and permissive insertion sites.
Osicka R; Osicková A; Basar T; Guermonprez P; Rojas M; Leclerc C; Sebo P
Infect Immun; 2000 Jan; 68(1):247-56. PubMed ID: 10603395
[TBL] [Abstract][Full Text] [Related]
5. Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis.
Dadaglio G; Moukrim Z; Lo-Man R; Sheshko V; Sebo P; Leclerc C
Infect Immun; 2000 Jul; 68(7):3867-72. PubMed ID: 10858196
[TBL] [Abstract][Full Text] [Related]
6. Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model.
Cheung GY; Xing D; Prior S; Corbel MJ; Parton R; Coote JG
Infect Immun; 2006 Dec; 74(12):6797-805. PubMed ID: 16982827
[TBL] [Abstract][Full Text] [Related]
7. Efficient Ex vivo stimulation of Mycobacterium tuberculosis-specific T cells by genetically detoxified Bordetella pertussis adenylate cyclase antigen toxoids.
Wilkinson KA; Simsova M; Schölvinck E; Sebo P; Leclerc C; Vordermeier HM; Dickson SJ; Brown JR; Davidson RN; Pasvol G; Levin M; Wilkinson RJ
Infect Immun; 2005 May; 73(5):2991-8. PubMed ID: 15845506
[TBL] [Abstract][Full Text] [Related]
8. Bordetella pertussis adenylate cyclase delivers chemically coupled CD8+ T-cell epitopes to dendritic cells and elicits CTL in vivo.
Fayolle C; Bauche C; Ladant D; Leclerc C
Vaccine; 2004 Dec; 23(5):604-14. PubMed ID: 15542180
[TBL] [Abstract][Full Text] [Related]
9. Enhanced ex vivo stimulation of Mycobacterium tuberculosis-specific T cells in human immunodeficiency virus-infected persons via antigen delivery by the Bordetella pertussis adenylate cyclase vector.
Connell TG; Shey MS; Seldon R; Rangaka MX; van Cutsem G; Simsova M; Marcekova Z; Sebo P; Curtis N; Diwakar L; Meintjes GA; Leclerc C; Wilkinson RJ; Wilkinson KA
Clin Vaccine Immunol; 2007 Jul; 14(7):847-54. PubMed ID: 17522328
[TBL] [Abstract][Full Text] [Related]
10. Bioengineering of
Ladant D
Toxins (Basel); 2021 Jan; 13(2):. PubMed ID: 33499260
[TBL] [Abstract][Full Text] [Related]
11. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.
Macdonald-Fyall J; Xing D; Corbel M; Baillie S; Parton R; Coote J
Vaccine; 2004 Oct; 22(31-32):4270-81. PubMed ID: 15474718
[TBL] [Abstract][Full Text] [Related]
12. Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: implication for the in vivo delivery of CD8(+) T cell epitopes into antigen-presenting cells.
Karimova G; Fayolle C; Gmira S; Ullmann A; Leclerc C; Ladant D
Proc Natl Acad Sci U S A; 1998 Oct; 95(21):12532-7. PubMed ID: 9770520
[TBL] [Abstract][Full Text] [Related]
13. Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus.
Saron MF; Fayolle C; Sebo P; Ladant D; Ullmann A; Leclerc C
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3314-9. PubMed ID: 9096390
[TBL] [Abstract][Full Text] [Related]
14. Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization.
Guiso N; Szatanik M; Rocancourt M
Microb Pathog; 1991 Dec; 11(6):423-31. PubMed ID: 1795632
[TBL] [Abstract][Full Text] [Related]
15. Development of an approach for the laboratory toxicological evaluation of Bordetella pertussis adenylate cyclase genetic toxoid constructs as multipurpose vaccines.
Prior S; Corbel MJ; Xing DK
Hum Vaccin; 2005; 1(4):151-9. PubMed ID: 17012877
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to Bordetella pertussis adenylate cyclase toxin in neonatal and maternal sera.
Arciniega JL; Hewlett EL; Edwards KM; Burns DL
FEMS Immunol Med Microbiol; 1993 Apr; 6(4):325-30. PubMed ID: 8499896
[TBL] [Abstract][Full Text] [Related]
17. Epitope mapping of monoclonal antibodies against Bordetella pertussis adenylate cyclase toxin.
Lee SJ; Gray MC; Guo L; Sebo P; Hewlett EL
Infect Immun; 1999 May; 67(5):2090-5. PubMed ID: 10225859
[TBL] [Abstract][Full Text] [Related]
18. Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells.
Ross PJ; Lavelle EC; Mills KH; Boyd AP
Infect Immun; 2004 Mar; 72(3):1568-79. PubMed ID: 14977963
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice.
Orr B; Douce G; Baillie S; Parton R; Coote J
Vaccine; 2007 Jan; 25(1):64-71. PubMed ID: 16916566
[TBL] [Abstract][Full Text] [Related]
20. Delivery of a MalE CD4(+)-T-cell epitope into the major histocompatibility complex class II antigen presentation pathway by Bordetella pertussis adenylate cyclase.
Loucká J; Schlecht G; Vodolánová J; Leclerc C; Sebo P
Infect Immun; 2002 Feb; 70(2):1002-5. PubMed ID: 11796640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
